Thu, March 25, 2021
Wed, March 24, 2021
Tue, March 23, 2021

Andrew Fein Maintained (BCRX) at Strong Buy with Increased Target to $19 on, Mar 24th, 2021

Andrew Fein of HC Wainwright & Co., Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy with Increased Target from $14 to $19 on, Mar 24th, 2021.

Andrew has made no other calls on BCRX in the last 4 months.



There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $9 on, Friday, January 22nd, 2021


This is the rating of the analyst that currently disagrees with Andrew


  • Liisa Bayko of "Evercore ISI Group" Initiated at Buy and Held Target at $12 on, Tuesday, November 24th, 2020